ArticleCell communication and signaling : CCS2026
C-di-AMP sensitizes colorectal cancer to CD47 antibodies by activating NF-κB to promote macrophage phagocytosis.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CD47-mediated efferocytosis in diseases: A comprehensive review.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveDeveloping effective therapeutic strategies for colorectal cancer (CRC) presents a significant clinical challenge. Although immune checkpoint blockade therapies, such as the CD47 blockade, have shown promise, their efficacy is often limited by suboptimal responses and associated toxicities. This study explores the potential of the gut microbial metabolite cyclic diadenosine monophosphate (c-di-AMP) to enhance the therapeutic efficacy of CD47 antibodies in treating CRC while mitigating its adverse effects.
methodsA subcutaneous tumor model was established to assess the therapeutic efficacy of c-di-AMP in combination with CD47 blockade for CRC treatment. Growth inhibition assays were performed to evaluate the direct effects of c-di-AMP on CRC cells. Cell removal assays, flow cytometry, and immunofluorescence were employed to investigate the impact of c-di-AMP on macrophage-mediated phagocytosis. Macrophage polarization phenotypes were characterized by flow cytometry and immunohistochemistry. Transcriptome sequencing was also conducted to elucidate the molecular mechanisms underlying the c-di-AMP-induced enhancement of macrophage phagocytic activity.
resultsOur results revealed that c-di-AMP, in combination with CD47 blockade, exerted potent anticancer effects in vivo. Mechanistically, c-di-AMP enhanced macrophage-mediated phagocytosis triggered by CD47 blockade by promoting M1 polarization and activating the NF-κB signaling pathway. Furthermore, c-di-AMP upregulated the expression of CD11b/CD18, thereby strengthening intercellular adhesion between macrophages and CRC cells, which further facilitated phagocytosis.
conclusionThese findings indicate that c-di-AMP may enhance the efficacy of CD47 blockade in CRC by promoting macrophage phagocytosis through NF-κB activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.